Global Antibiotic R&D Partnership (GARDP) (@gardp_amr) header
Global Antibiotic R&D Partnership (GARDP) (@gardp_amr) profile picture

Putting public health needs at the centre of antibiotic R&D to address the crisis of antimicrobial resistance (AMR). https://teapawt.org/t.co/JVGd4yjvnv

Switzerland and worldwide
Joined January 2019
Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)Photo by Global Antibiotic R&D Partnership (GARDP) (@gardp_amr)
Geneva is full of people working on global health, which made the Geneva Health Forum 2026 a great place for GARDP to be. We brought two posters: 🔬 The AMR brain drain, and how REVIVE can help the antimicrobial R&D community stay connected and share knowledge. 💊 The @DNDi-GARDP CMC platform, developed with DNDi, showing how shared specialist capabilities can make product development stronger and create more sustainable routes to new medicines. We also joined a participatory roundtable on strengthening synergies with health product development partners in Geneva, looking at how PDPs, universities, research institutions, start-ups and companies can work together more effectively. The conversation continues in 2027 with two follow-up seminars, aimed at turning these connections into real opportunities to collaborate. Developing the next health innovation is only part of the challenge. It also takes the expertise, capabilities and partnerships to get promising ideas to the people who need them. #GenevaHealthForum #GlobalHealth #AMR #GARDP #REVIVE
2
2
233
Improving access to antibiotics requires coordinated efforts across research, diagnostics, stewardship and supply, alongside the development of new treatments. At the ReAct Asia Pacific Regional Conference on AMR in Jakarta, GARDP co-sponsored the conference, moderated a panel on equitable access to essential antibiotics and diagnostics. Speaking at the conference, GARDP Global Access Director Regina Osih emphasised the importance of turning evidence into action: “This gathering of AMR actors in Asia Pacific and beyond was an opportunity to re-engage and refresh GARDP's engagement around translating evidence to policy and action at the country level. Access to antibiotics cannot happen in a vacuum, and coordination across sectors and development of a whole of society approach will yield sustainable results in the future.” GARDP also participated in the High-Level Dialogue on the Future of AMR in the Asia-Pacific, contributing to discussions on strengthening the region’s response to antimicrobial resistance and improving access to effective treatments. @reactgroup I @KemenkesRI I @gstrategylab I @ICARS_global I Sida - Styrelsen för internationellt utvecklingssamarbet #AMR #AntibioticAccess
1
2
1
4
472
Is it ethical not to test medicines in newborns? In a new @FinancialTimes opinion piece, GARDP's Manica Balasegaram argues that excluding newborns from research could be putting them at great risk. Newborns are often excluded from clinical trials to protect them. But doing so could make them more vulnerable because it means doctors won’t have the evidence they need to treat them when they get sick. 💊 Of the 40 new antibiotics approved between 2000 and 2022, only 4 were tested and approved for newborns. That leaves doctors with less evidence on the right dose, duration and treatment approach. The question isn't only whether research in newborns is ethical. Can we justify not doing it? 👉 Read the full piece by Manica: ft.pulse.ly/nyflqmbvqx @Manica_amr #AMR #NewbornHealth
1
235
🍼 When AMR threatens newborn lives, the treatment gap is enormous. Up to 3 million newborns develop serious infections each year, which can lead to life-threatening sepsis. GARDP is responding on multiple fronts: 🔬 NeoOBS: evidence from 3,200+ newborns across 11 countries. 🧪 NeoSep1: evaluating antibiotic combinations and doses, targeting 3,000 newborns across Africa and Asia by 2028. 💊 Exploring cefiderocol for highly drug-resistant infections in newborns. From evidence generation to clinical trials and new treatment options, we're working to give newborns a better chance of survival. AMR is BIG. Our response is BIGGER. 🔗 gardp.pulse.ly/wvjh1k7ubm #AMRIsBIG #OurResponseIsBigger
1
1
3
280
🔬 Research ready for the spotlight? One week left to submit your abstract for #ACC2027, the open-access, virtual conference on antimicrobial chemotherapy, jointly organized by @BSACandJAC and GARDP with the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) as its collaborating organization for 2027. Submit for poster or oral + poster consideration. ⏳ Deadline: 16 Nov 2026, 17:00 GMT 👉 acc-conference.com/#posters
1
1
406
The 2027 edition of the Antimicrobial Chemotherapy Conference (#ACC2027) features an expanded three-day programme and new opportunities to connect and share research. New this year: ACC Connect Circles and a dedicated day on One Health AMR, alongside the latest research across antimicrobial discovery, development and access. Jointly organised by @BSACandJAC and GARDP, with European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) as the collaborating organization for 2027. 📅 Abstract deadline: 16 Nov, 17:00 GMT. 👉 Register: bsac.eventsair.com/antimicro… 👉 Submit an abstract: acc-conference.com/#posters #AntimicrobialResistance #OneHealth
1
2
1
4
267
🇧🇩Bangladesh has joined the NeoSep1 clinical trial, expanding this important research on much-needed effective antibiotic treatment regimens for newborns with sepsis. Thank you to the researchers, clinicians, nurses and hospital teams helping to generate evidence that could improve care for newborn babies affected by severe infections. #NeoSep1 #NeonatalSepsis #AMR @innovativectu I @CityStGeorges I @Penta_ID
1
1
269
🎂 Congratulations to the @MedsPatentPool on 10 years of MedsPaL! GARDP has worked with MPP on patent landscape assessments of ceftazidime–avibactam and aztreonam–avibactam, helping inform access strategies, market shaping, affordability and potential generic market entry in low- and middle-income countries. Peter Beyer, Deputy Executive Director of GARDP, highlights the importance of this work: “Access to effective antibiotics depends not only on developing new treatments, but also on ensuring they can reach the people who need them. By making patent and licensing information transparent and easily accessible, MedsPaL provides a valuable resource for organisations working to expand access to medicines in low- and middle-income countries.” #AccessToMedicines #Antibiotics
💡 Access to medicines starts with access to information. 🤝🏽 For the past decade, MedsPaL has helped governments, procurement agencies, manufacturers, researchers and public health organisations navigate complex patent and licensing landscapes by making critical information freely available and easier to access. 🌐 Since its launch in 2016, MedsPaL has expanded from around 4,000 patent applications covering three disease areas to a global resource containing information on 217 health products, 33,800 patent applications and 86 public licences across 203 jurisdictions. 🎂 As MedsPaL marks its 10th anniversary, we're proud to reflect on how transparency can support informed decision-making and help advance access to health technologies around the world. 🙏🏽 We're grateful to the many organisations and individuals who have contributed to MedsPaL's development over the past decade, and to our funders and supporters, including @UNITAID, @SwissDevCoop, Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH, the Government of Japan, and @coeff_giving, whose contributions help sustain and strengthen MPP's patent information activities. 🗞️ Read our anniversary statement and discover how @DrDuneton (Unitaid), @JayasreeKIyer (@AtMIndex), @Peter_Beyer (Global Antibiotic R&D Partnership (@gardp_amr), Harm Veerkamp (@IDA_Foundation) Nikola Trifunovic (i+solutions), Jithu Krishnan J (@SunPharma_Live), Viktor Cherniavskyi (@UNDP Global Health Supply Centre), Marion (Amy) Dietterich (@WIPO World Intellectual Property Organization), and @lorenzomoja (@WHO) have used and supported MedsPaL throughout its journey. 🔗 lnkd.in/eX4B4but Access MedsPaL > medspal.org/ #MedsPaL #AccessToMedicines #GlobalHealth #PublicHealth #HealthInnovation
1
4
296
📚 What do antibiotic resistance breakers, faecal microbiota transplantation, and combination regimens have in common? They’re among 8 new terms added to the REVIVE Encyclopaedia, helping unpack the science behind antibiotic research, clinical trials and infectious disease treatment. Explore the latest entries: gardp.pulse.ly/ipav3darlf #AMR #Antibiotics #REVIVE #GARDP
2
1
4
258
At the 2026 @UNHumanRights Social Forum in Geneva, GARDP’s Peter Beyer moderated a panel discussion on equitable access to medicines, vaccines, medical equipment and health products. Speaking about the importance of building affordability into antibiotic development from the outset, Peter said: “When we select the molecules we want to advance for antibiotic-resistant infections, we need to consider access at the preclinical stage, to keep costs low and ensure the product can ultimately be affordable.” #AMR #RightToHealth
1
1
3
205
🤝 Last week in Berlin, the Public Health Center of Ukraine brought together international partners to strengthen the country’s response to antimicrobial resistance (AMR), with GARDP among the supporting partners. For GARDP, responsible access means not only making antibiotics available, but working with partners to ensure they are introduced and used in ways that protect their effectiveness. #AMR #AntimicrobialResistance #Ukraine #GlobalHealth @ChariteBerlin
1
2
249
Global Antibiotic R&D Partnership (GARDP) retweeted
The 2026 Social Forum takes place on 29 and 30 October at @UNGeneva. This year's forum focuses on how international cooperation can help realize the right to health. Info ➔ohchr.org/en/events/forums/2…
10
10
21
7,824
💊 What does a bigger response to drug-resistant serious bacterial infections look like? It means advancing new antibiotics against some of the hardest-to-treat infections, while expanding access to effective treatments that already exist. 🧪 GARDP is co-developing BWC0977 with India-based Bugworks Research, a novel broad-spectrum antibiotic candidate active against some of the most difficult-to-treat drug-resistant Gram-negative bacteria. 🌍 We’re also working to expand access to cefiderocol, an important treatment option for serious infections where resistance has left patients with limited options. AMR is BIG. Our response is BIGGER. 🔗 gardp.pulse.ly/s6zpwhlj6l #AMRIsBIG #OurResponseIsBigger #AMR
1
1
1
216
📺 Missed our webinar? The recording is now available. In 'From approval to access: A new model for delivering effective antibiotics', experts discussed why millions of people in high-burden settings still lack access to life-saving antibiotics, and what needs to change to close this gap. The conversation also explored GARDP's public-private partnership approach and the approval of zoliflodacin in Thailand just six months after its approval by the US FDA. 🎥 Watch the recording: youtu.pulse.ly/16dpe6qugs
2
1
4
414
🎉 Congratulations to @DNDi on welcoming Kenya’s KEMRI to the Dengue Alliance! 🇰🇪 This is an exciting step for dengue research, bringing African expertise and evidence into a global collaboration to advance new treatments. With KEMRI on board, the Alliance grows stronger in its ambition to turn research into better treatment options for people affected by dengue.
🌍We are pleased to announce that the Kenya Medical Research Institute @KEMRI_Kenya has joined the Dengue Alliance, making Kenya the first African country part of this global partnership dedicated to advancing dengue treatment research. 👉 More details: dndi.org/press-releases/2026…
3
269